|
Hypertensive disease
|
0.560 |
Biomarker
|
group |
BEFREE |
GLP-1R activation attenuates cardiovascular complications of arterial hypertension by reduction of vascular inflammation through selective actions requiring the endothelial but not the myeloid cell GLP-1R.
|
31747801 |
2020 |
|
Hypertensive disease
|
0.560 |
Biomarker
|
group |
BEFREE |
The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.
|
31729903 |
2020 |
|
Hypertensive disease
|
0.560 |
Biomarker
|
group |
BEFREE |
The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, has been shown to prevent pulmonary hypertension in monocrotaline-exposed rats.
|
31336911 |
2019 |
|
Hypertensive disease
|
0.560 |
Biomarker
|
group |
BEFREE |
We here report that repeated lateral ventricular (LV) injection of GLP-1R agonist, liraglutide, once daily for 15 days counteracted the development of hypertension in spontaneously hypertensive rats (SHR).
|
31537818 |
2019 |
|
Hypertensive disease
|
0.560 |
Biomarker
|
group |
BEFREE |
The purpose of this review is to explore GLP-1 RA actions not only in cardiovascular risk factors (glucose, weight, and hypertension) but also the possible effects on established cardiovascular disease.
|
29805980 |
2018 |
|
Hypertensive disease
|
0.560 |
Biomarker
|
group |
BEFREE |
In contrast, selective SDF-1 receptor blockade with AMD3100 reduced urinary sodium excretion and aggravated glomerular hypertension in the Glp1r(+/+) diabetic-prone mice.
|
27475229 |
2016 |
|
Hypertensive disease
|
0.560 |
Biomarker
|
group |
CTD_human |
A custom rat and baboon hypertension gene array to compare experimental models.
|
22228705 |
2012 |
|
Hypertensive disease
|
0.560 |
Biomarker
|
group |
RGD |
We report here that centrally and peripherally administered GLP-1R agonists dose-dependently increased blood pressure and heart rate.
|
12093887 |
2002 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
In study B, individuals with T2DM randomly received GLP-1 RA liraglutide (titrated up to 1.8 mg daily) or titrated insulin glargine for 12 wk.
|
31415908 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
GLP-1 also controls glucose homeostasis, which lead to the approval of GLP-1 receptor agonists for treatment of diabetes type II.
|
31759971 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
While these data suggest the potential of small molecule GLP-1R PAMs for T2DM treatment, further optimization is still required towards a clinical candidate.
|
31596080 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Whilst such effects of GIP antagonism are yet to be evaluated in humans, recent studies using combined GIP and GLP-1 agonists have shown weight reduction and improved glycaemic control in people with type 2 diabetes (T2D).
|
31759125 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Next, we present the results from major randomized controlled trials on the use of GLP-1 receptor agonists for managing type 2 diabetes, and emerging data on treating obesity and prediabetes.
|
31392745 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The lamprey GLP-1 analogue shows therapeutic promise for treatment of patients with obesity-related Type 2 diabetes.
|
31539596 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
A randomized, double-blind, placebo-controlled, 4-week phase 1 multiple-ascending-dose study (NCT02411825) in 36 overweight to obese subjects with type 2 diabetes mellitus receiving SAR425899 demonstrated decreased body weight with a safety profile comparable with GLP-1R agonists.
|
31808298 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia.
|
31801807 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Liraglutide is a GLP-1 receptor agonist recently approved for Type-II diabetes (T2D) treatment with superior hypoglycemic effect while also improving cardiovascular function for the patients.
|
31838207 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and liraglutide is the first GLP-1RA to be approved for the treatment of obesity in patients with and without T2DM.<b>Areas covered</b>: In this review of relevant published material, the authors summarize the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment of obesity.<b>Expert opinion</b>: Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake, independent of its glucose-lowering effects.
|
31790314 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
|
31699625 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) comparing SGLT2is plus Dipeptidyl-Peptidase 4 inhibitors (SGLT2is/DPP4is) or glucagon like peptide-1 receptor agonists (SGLT2is/GLP-1RAs) against SGLT2is as monotherapy or add-on to metformin in T2DMs.
|
31642583 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nevertheless, prior animal and human studies on incretin mimetics, glucagon like peptide-1 receptor agonists (GLP-1 RA) approved for T2DM treatment, have provided indirect evidence that they may also ameliorate NAFLD/NASH, whereas dipeptidyl dipeptidase-4 inhibitors (DDP-4i) were not better than placebo in reducing liver fat in T2DM patients with NAFLD.
|
30961499 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cardiovascular outcome trials (eg, LEADER [Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcome Results], SUSTAIN-6) demonstrated that GLP-1 (glucagon-like peptide 1) analogs including liraglutide reduce the risk of cardiovascular events in type 2 diabetes mellitus.
|
31747801 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, L-SGgly can significantly increase (p < 0.01) GLP-1 levels and decrease (p < 0.01) IL-6 levels in T2DM rat serum.
|
31586692 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.
|
31673896 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Insulin degludec/liraglutide (IDegLira) is a fixed-ratio combination (FRC) of basal insulin and glucagon-like protein-1 receptor agonist (GLP-1 RA) that has demonstrated glycemic and metabolic benefits in patients with type 2 diabetes mellitus (T2DM) in both randomized controlled trials and real-world studies.
|
31808132 |
2020 |